Patents by Inventor Arto Urtti
Arto Urtti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969505Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.Type: GrantFiled: April 4, 2022Date of Patent: April 30, 2024Assignee: UPM-KYMMENE CORPORATIONInventors: Heli Paukkonen, Vili-Veli Auvinen, Marjo Yliperttula, Patrick Laurën, Arto Urtti, Timo Laaksonen, Arto Merivaara, Tiina Hakkarainen, Outi Monni, Anne Mäkelä, Petter Somersalo, Piia-Riitta Karhemo, Heikki Joensuu, Raili Koivuniemi, Kari Luukko, Markus Nuopponen
-
Patent number: 11850306Abstract: The present disclosure relates to method for drying hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing polyethylene glycol, providing trehalose, mixing the hydrogel, the polyethylene glycol and the trehalose to obtain a mixture, and freeze drying the mixture to obtain a dried hydrogel comprising nanofibrillar cellulose. The present disclosure relates to a freeze-dryable hydrogel comprising nanofibrillar cellulose, to a freeze-dried hydrogel comprising nanofibrillar cellulose, and to a medical hydrogel comprising nanofibrillar cellulose and one or more therapeutic agent(s).Type: GrantFiled: December 15, 2017Date of Patent: December 26, 2023Assignee: UPM-KYMMENE CORPORATIONInventors: Vili-Veli Auvinen, Heli Paukkonen, Marjo Yliperttula, Arto Urtti, Tiina Hakkarainen, Patrick Laurén, Mikko Kunnari, Timo Laaksonen, Mingwei Li, Kari Luukko
-
Publication number: 20220249378Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.Type: ApplicationFiled: April 4, 2022Publication date: August 11, 2022Inventors: Heli PAUKKONEN, Vili-Veli AUVINEN, Marjo YLIPERTTULA, Patrick LAURÉN, Arto URTTI, Timo LAAKSONEN, Arto MERIVAARA, Tiina HAKKARAINEN, Outi MONNI, Anne MÄKELÄ, Petter SOMERSALO, Piia-Riitta KARHEMO, Heikki JOENSUU, Raili KOIVUNIEMI, Kari LUUKKO, Markus NUOPPONEN
-
Patent number: 11324701Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.Type: GrantFiled: August 25, 2017Date of Patent: May 10, 2022Assignee: UPM-KYMMENE CORPORATIONInventors: Heli Paukkonen, Vili-Veli Auvinen, Marjo Yliperttula, Patrick Laurén, Arto Urtti, Timo Laaksonen, Arto Merivaara, Tiina Hakkarainen, Outi Monni, Anne Mäkelä, Petter Somersalo, Piia-Riitta Karhemo, Heikki Joensuu, Raili Koivuniemi, Kari Luukko, Markus Nuopponen
-
Publication number: 20210190765Abstract: The present invention relates a method for chemical testing, comprising culturing cells in a first plant-derived nanofibrillar cellulose (NFC)hydrogel to obtain in vivo like cells; exposing the in vivo like cells to a test chemical; optionally within another plant-derived NFC hydrogel; incubating the exposed in vivo like cells; detecting during or after incubating, the impact of the test chemical on the in vivo like cells by at least one detection; and removing the plant-derived NFC hydrogel at least once at any stage after obtaining the in vivo like cells and before at least one detection used for detecting the impact of the test chemical on the in vivo like cells. The invention further relates to the use of plant-derived NFC hydrogel in a method for chemical testing, the use of in vivo like cells obtained by culturing cells in plant-derived NFC hydrogel for chemical testing and to a kit for chemical testing comprising plant-derived NFC hydrogel, instructions and a cell or test chemical library.Type: ApplicationFiled: March 2, 2021Publication date: June 24, 2021Inventors: Marjo Yliperttula, Arto Urtti, Yan-Ru Lou, Melina Malinen, Patrick Laurén, Liisa Kanninen, Kirsti Johanna Niklander, Petter Somersalo, Riina Harjumäki
-
Publication number: 20210127663Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.Type: ApplicationFiled: August 25, 2017Publication date: May 6, 2021Inventors: Heli PAUKKONEN, Vili-Veli AUVINEN, Marjo YLIPERTTULA, Patrick LAURÉN, Arto URTTI, Timo LAAKSONEN, Arto MERIVAARA, Tiina HAKKARAINEN, Outi MONNI, Anne MÄKELÄ, Petter SOMERSALO, Piia-Riitta KARHEMO, Heikki JOENSUU, Raili KOIVUNIEMI, Kari LUUKKO, Markus NUOPPONEN
-
Patent number: 10976308Abstract: The present invention relates a method for chemical testing, comprising culturing cells in a first plant-derived nanofibrillar cellulose (NFC) hydrogel to obtain in vivo like cells; exposing the in vivo like cells to a test chemical; optionally within another plant-derived NFC hydrogel; incubating the exposed in vivo like cells; detecting during or after incubating, the impact of the test chemical on the in vivo like cells by at least one detection; and removing the plant-derived NFC hydrogel at least once at any stage after obtaining the in vivo like cells and before at least one detection used for detecting the impact of the test chemical on the in vivo like cells. The invention further relates to the use of plant-derived NFC hydrogel in a method for chemical testing, the use of in vivo like cells obtained by culturing cells in plant-derived NFC hydrogel for chemical testing and to a kit for chemical testing comprising plant-derived NFC hydrogel, instructions and a cell or test chemical library.Type: GrantFiled: December 18, 2015Date of Patent: April 13, 2021Assignee: UPM-KYMMENE CORPORATIONInventors: Marjo Yliperttula, Arto Urtti, Yan-Ru Lou, Melina Malinen, Patrick Laurén, Liisa Kanninen, Kirsti Johanna Niklander, Petter Somersalo, Riina Harjumäki
-
Publication number: 20200078305Abstract: The present disclosure relates to method for drying hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing polyethylene glycol, providing trehalose, mixing the hydrogel, the polyethylene glycol and the trehalose to obtain a mixture, and freeze drying the mixture to obtain a dried hydrogel comprising nanofibrillar cellulose. The present disclosure relates to a freeze-dryable hydrogel comprising nanofibrillar cellulose, to a freeze-dried hydrogel comprising nanofibrillar cellulose, and to a medical hydrogel comprising nanofibrillar cellulose and one or more therapeutic agent(s).Type: ApplicationFiled: December 15, 2017Publication date: March 12, 2020Inventors: Vili-Veli AUVINEN, Heli PAUKKONEN, Marjo YLIPERTTULA, Arto URTTI, Tiina HAKKARAINEN, Patrick LAURÉN, Mikko KUNNARI, Timo LAAKSONEN, Mingwei LI, Kari LUUKKO
-
Publication number: 20180024121Abstract: The present invention relates a method for chemical testing, comprising culturing cells in a first plant-derived nanofibrillar cellulose (NFC) hydrogel to obtain in vivo like cells; exposing the in vivo like cells to a test chemical; optionally within another plant-derived NFC hydrogel; incubating the exposed in vivo like cells; detecting during or after incubating, the impact of the test chemical on the in vivo like cells by at least one detection; and removing the plant-derived NFC hydrogel at least once at any stage after obtaining the in vivo like cells and before at least one detection used for detecting the impact of the test chemical on the in vivo like cells. The invention further relates to the use of plant-derived NFC hydrogel in a method for chemical testing, the use of in vivo like cells obtained by culturing cells in plant-derived NFC hydrogel for chemical testing and to a kit for chemical testing comprising plant-derived NFC hydrogel, instructions and a cell or test chemical library.Type: ApplicationFiled: December 18, 2015Publication date: January 25, 2018Inventors: Marjo Yliperttula, Arto Urtti, Yan-Ru Lou, Melina Malinen, Patrick Laurén, Liisa Kanninen, Johanna Niklander, Petter Somersalo, Riina Harjumäki
-
Publication number: 20150011518Abstract: A drug-dissolved non-aqueous liquid composition containing a drug, dioleylphosphatidylcholine, tocopherol and an organic solvent, wherein the blend concentration ratio between the dioleylphosphatidylcholine and the tocopherol falls within the range of 75/25 to 25/75, the blend concentration of the dioleylphosphatidylcholine falls within the range of 15 to 85% (w/w), the blend concentration of the tocopherol falls within the range of 15 to 85% (w/w), and the phase of the non-aqueous liquid composition changes into a non-lamellar liquid crystal upon contact with water, a phosphate buffer, a body fluid, a lacrimal fluid or a vitreous fluid.Type: ApplicationFiled: January 30, 2013Publication date: January 8, 2015Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Kazuhito Yamada, Arto Urtti, Mechthild Burmester
-
Patent number: 7596400Abstract: The present invention relates to an electrode detector, which comprises a contact electrode part adjustable to tissue, or being in touch with it and which contact electrode part is for monitoring biopotential or other physical magnitude, a conducting wire (2) attached to the contact electrode part, electroconductive material, non-electroconductive material and electronics processing the signal.Type: GrantFiled: October 26, 2004Date of Patent: September 29, 2009Inventors: Antti Valjakka, Arto Urtti, Janne Ahonen
-
Patent number: 7549749Abstract: The present invention relates to a visual stimulator, which comprises a light stimulation source, a regulable attenuator of light, mirrors for reflecting light and light detectors. The visual stimulator in accordance with the invention comprises a mirror chamber and a mirror tube constructed of mirrors in which the reflecting points of the mirrors form various angles with respect to each other, and which have been connected to each other such that light beams disperse from the mirror tube to the mirror chamber without hindrance regardless of the location of the object to be examined or a part of it in the mirror chamber and though the location of the object or a part of it would vary in certain limits in the mirror chamber, and that to one end of the mirror tube, viewed away from the mirror chamber a light stimulation source has been directed.Type: GrantFiled: October 26, 2004Date of Patent: June 23, 2009Inventors: Antti Valjakka, Arto Urtti, Janne Ahonen
-
Publication number: 20050131498Abstract: The present invention relates to a visual stimulator, which comprises a light stimulation source, a regulable attenuator of light, mirrors for reflecting light and light detectors. The visual stimulator in accordance with the invention comprises a mirror chamber and a mirror tube constructed of mirrors in which the reflecting points of the mirrors form various angles with respect to each other, and which have been connected to each other such that light beams disperse from the mirror tube to the mirror chamber without hindrance regardless of the location of the object to be examined or a part of it in the mirror chamber and though the location of the object or a part of it would vary in certain limits in the mirror chamber, and that to one end of the mirror tube, viewed away from the mirror chamber a light stimulation source has been directed.Type: ApplicationFiled: October 26, 2004Publication date: June 16, 2005Inventors: Antti Valjakka, Arto Urtti, Janne Ahonen
-
Publication number: 20050119544Abstract: The present invention relates to an electrode detector, which comprises a contact electrode part adjustable to tissue, or being in touch with it and which contact electrode part is for monitoring biopotential or other physical magnitude, a conducting wire (2) attached to the contact electrode part, electroconductive material, non-electroconductive material and electronics processing the signal.Type: ApplicationFiled: October 26, 2004Publication date: June 2, 2005Inventors: Antti Valjakka, Arto Urtti, Janne Ahonen
-
Publication number: 20030064954Abstract: The present invention discloses amphiphilic 1,4-dihydropyridine derivatives useful for the preparation of a composition for delivering nucleotide containing compounds into a target cell and/or its nucleus. Said composition comprises 1,4-dihydropyridine derivatives having a good DNA condensing capacity and capability of self-association. Also disclosed are composition comprising said derivatives complexed with nucleotide containing compounds as well methods for the producing of said complexes. The invention is also related to the use of said 1,4-dihydropyridine derivatives for manufacturing systems for delivering nucleotide containing compounds useful in gene therapy and DNA vaccination.Type: ApplicationFiled: August 22, 2002Publication date: April 3, 2003Inventors: Arto Urtti, Zanna Hyvonen, Aiva Plotniece, Natalia Makarova, Inese Reine, Gunars Tirzitis, Brigita Vigante, Brigita Cekavicus, Andulis Shmidlers, Aivars Krauze, Raivis Zhalubovskis, Gunars Duburs, Mikko Turunen, Seppo Yla-Herttuala, Ilpo Jaaskelainen, Marjo-Riitta Toppinen
-
Patent number: 6183771Abstract: Transdermal administration of levosimenden or (−)-[[4-(1,4,5,6-tetahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono]propanedinitrile or a pharmaceutically acceptable salt thereof is disclosed. Transdermal preparations of levosimenden can be in the form of e.g. ointment, emulsion, lotion, solution, gel, cream, patch or transdermal delivery device including iontophoretic device.Type: GrantFiled: March 23, 1999Date of Patent: February 6, 2001Assignee: Orion CorporationInventors: Arto Urtti, Jouni Hirvonen, Lasse Lehtonen, Saila Antila
-
Patent number: 5977180Abstract: Anandamide analogues useful for the treatment of intraocular hypertension, as well as ophthalmic compositions comprising the same and a cyclodextrin, and methods of use of these compounds to treat intraocular hypertension.Type: GrantFiled: January 10, 1997Date of Patent: November 2, 1999Inventors: David W. Pate, Tomi Jarvinen, Kristina Jarvinen, Arto Urtti
-
Patent number: 5631297Abstract: Anandamides useful for the treatment of intraocular hypertension, as well as ophthalmic compositions comprising the same and a cyclodextrin, and methods of use of these compounds to treat intraocular hypertension.Type: GrantFiled: July 11, 1994Date of Patent: May 20, 1997Inventors: David W. Pate, Tomi Jarvinen, Kristiina Jarvinen, Arto Urtti
-
Patent number: 5436350Abstract: The object of the invention are bispilocarpates useful in the treatment of glaucoma and having the formula ##STR1## wherein A) Y is hydrogen or the acyl group ##STR2## and W is the group --O--A--O--Z--Y', wherein Y' is hydrogen or the acyl group ##STR3## the groups R and R' having different meanings and may be the same or different and A is an aliphatic, aromatic or heterocyclic bridging group, and --Z--Y' is ##STR4## or B) W is OR, wherein R has the same meaning as above, Y is ##STR5## where R' has the same meaning as above, B means the same as A and Z'--OR' is ##STR6## or C) W and Y together mean ##STR7## where the symbols have the same meanings as above.Type: GrantFiled: May 26, 1993Date of Patent: July 25, 1995Inventors: Tomi Jarvinen, Pekka Peura, Pekka Suhonen, Arto Urtti, Hannu Hanhijarvi, Esko Pohjala
-
Patent number: 5304569Abstract: Compounds of formula: ##STR1## where X is --CH.sub.2 --, --CH(CH.sub.3)--, --CHR.sub.3 --CH.sub.2 -- or --CR.sub.3 .dbd.CH-- and R.sub.1, R.sub.2 and R.sub.3, which can be the same or different, are each H or CH.sub.3 or a stereoisomer or pharmaceutically acceptable salt thereof, and pharmaceutical compositions containing them, are useful for lowering intraocular pressure in a mammal, e.g. in the treatment of glaucoma.Type: GrantFiled: October 31, 1990Date of Patent: April 19, 1994Assignee: Orion-yhtyma OyInventors: Risto Lammintausta, Arto Karjalainen, Ewen MacDonald, Arto Urtti, Raimo Virtanen, Thomas Yorio